BT-062 is an antibody-drug conjugate binding to CD138, which is over-expressed on multiple myeloma (NYSE:MM) and a variety of solid tumors. BT-062 has shown good tolerability in clinical phase I/II studies and achieved clinical benefit in MM patients. Additionally, BT-062 demonstrated very good efficacy in solid tumor animal models (e.g. triple negative breast cancer), making it a promising candidate for development in solid tumor indications.
Broadcast live, record and publish your investor, corporate and analyst videos on 3B NEXUS for our targeted distribution. 3bnexus.com